The Experts below are selected from a list of 1002 Experts worldwide ranked by ideXlab platform
Xiaoyuan Chen - One of the best experts on this subject based on the ideXlab platform.
-
tailoring platinum iv amphiphiles for self targeting all in one assemblies as precise multimodal Theranostic Nanomedicine
ACS Nano, 2018Co-Authors: Qingfei Zhang, Xing-jie Liang, Xiaoyuan Chen, Haihua Xiao, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Drug, targeting ligand, and imaging agent are the three essential components in a nanoparticle-based drug delivery system. However, tremendous batch-to-batch variation of composition and drug content typically accompany the current approaches of building these components together. Herein, we report the design of photoactivatable platinum(IV) (Pt(IV)) amphiphiles containing one or two hydrophilic lactose targeting ligands per hydrophobic Pt(IV) prodrug for an all-in-one precise Nanomedicine. Self-assembly of these Pt(IV) amphiphiles results in either micelle or vesicle formation with a fixed Pt/targeting moiety ratio and a constantly high content of Pt. The micelles and vesicles are capable of hepatoma cell-targeting, fluorescence/Pt-based CT imaging and have shown effective anticancer efficacy under laser irradiation in vitro and in vivo. This photoactivatable, active self-targeting, and multimodal Theranostic amphiphile strategy shows great potential in constructing precise Nanomedicine.
-
Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine
2018Co-Authors: Qingfei Zhang, Xing-jie Liang, Xiaoyuan Chen, Haihua Xiao, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Drug, targeting ligand, and imaging agent are the three essential components in a nanoparticle-based drug delivery system. However, tremendous batch-to-batch variation of composition and drug content typically accompany the current approaches of building these components together. Herein, we report the design of photoactivatable platinum(IV) (Pt(IV)) amphiphiles containing one or two hydrophilic lactose targeting ligands per hydrophobic Pt(IV) prodrug for an all-in-one precise Nanomedicine. Self-assembly of these Pt(IV) amphiphiles results in either micelle or vesicle formation with a fixed Pt/targeting moiety ratio and a constantly high content of Pt. The micelles and vesicles are capable of hepatoma cell-targeting, fluorescence/Pt-based CT imaging and have shown effective anticancer efficacy under laser irradiation in vitro and in vivo. This photoactivatable, active self-targeting, and multimodal Theranostic amphiphile strategy shows great potential in constructing precise Nanomedicine
-
Polymeric Materials for Theranostic Applications
Pharmaceutical Research, 2014Co-Authors: Zhe Wang, Gang Niu, Xiaoyuan ChenAbstract:Nanotechnology has continuously contributed to the fast development of diagnostic and therapeutic agents. Theranostic Nanomedicine has encompassed the ongoing efforts on concurrent molecular imaging of biomarkers, delivery of therapeutic agents, and monitoring of therapy response. Among these formulations, polymer-based Theranostic agents hold great promise for the construction of multifunctional agents for translational medicine. In this article, we reviewed the state-of-the-art polymeric nanoparticles, from preparation to application, as potential Theranostic agents for diagnosis and therapy. We summarized several major polymer formulas, including polymeric conjugate complexes, nanospheres, micelles, and dendrimers for integrated molecular imaging and therapeutic applications.
-
LOMIN: Moving Theranostics from bench to bedside
2011 IEEE NIH Life Science Systems and Applications Workshop (LiSSA), 2011Co-Authors: Seulki Lee, Xiaoyuan ChenAbstract:The Laboratory of Molecular Imaging and Nanomedicine (LOMIN) was initiated in 2009 at the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering and has been led by Xiaoyuan (Shawn) Chen. Currently, LOMIN has grown to over 25 members who work together in diverse fields to develop Theranostic molecular imaging tools and drug delivery systems. LOMIN is an interdisciplinary group divided into different sections based on expertise, but not divided by research projects. The three interdisciplinary and versatile groups, the PET/Optical Imaging Probe Section, the Biological Molecular Imaging Section and the Theranostic Nanomedicine Section, consist of chemists, engineers, biologists, and clinicians working together to transfer biomedical technology from the bench to the bedside. LOMIN works cohesively on its main mission to improve molecular imaging strategies for better understanding of biology, early diagnosis of disease, monitoring therapies and guiding drug discovery and development. In addition, special emphasis is placed on developing high sensitivity nanosensors for biomarker detection and Theranostic Nanomedicine for imaging, gene and drug delivery and therapy monitoring. LOMIN has developed novel imaging agents for targeting of various biological processes and monitoring therapies that have been slated for clinical trials. The future of LOMIN is to expand collaborations in order to apply lead imaging and therapeutic agents to the clinic. In this presentation, LOMIN will be introduced with our representative up-to-date research projects.
-
Moving Theranostics trom bench to bedside in an interdisciplinary research team.
Therapeutic delivery, 2011Co-Authors: Magdalena Swierczewska, Seulki Lee, Xiaoyuan ChenAbstract:The Laboratory of Molecular Imaging and Nanomedicine of the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health has been led by Xiaoyuan Chen since 2009. The Laboratory of Molecular Imaging and Nanomedicine contains three interdisciplinary, versatile groups: the Theranostic Nanomedicine; PET/Optical Imaging Probe; and Biological Molecular Imaging Sections, consisting of chemists, engineers, biologists and clinicians working together to transfer biomedical technology from bench to bedside. To find out more about our laboratory and meet our group, please visit us at www.nibib.nih.gov/Research/Intramural/xchen.
Youn Soo Sohn - One of the best experts on this subject based on the ideXlab platform.
-
Design of a Novel Theranostic Nanomedicine (III): Synthesis and Physicochemical Properties of Tumor-Targeting Cisplatin Conjugated to a Hydrophilic Polyphosphazene.
International journal of nanomedicine, 2020Co-Authors: Basavaraj R Patil, Prakash G Avaji, Yong Joo Jun, Hwa Jeong Lee, Su Yeon Kang, Da Hee Jung, Youn Soo SohnAbstract:Purpose A new Theranostic Nanomedicine involving anticancer-active cisplatin moiety was designed to study its tumor-targeting properties as well as its drug efficacy and toxicity. Methods A cisplatin carrier polymer was prepared by grafting equimolar polyethylene glycol of a molecular weight of 550 (PEG550) and aminoethanol to the poly(dichlorophosphazene) backbone. Cisplatin was conjugated to the carrier polymer using cis-aconitic acid as a linker. Results The cisplatin-loaded polyphosphazene, named "Polycisplatin" was found to be amphiphilic in aqueous solution and self-assembled into nanoparticles with an average particle size of 18.6 nm in diameter. The time-dependent organ distribution study of Cy5.5-labeled Polycisplatin in the A549-tumor-bearing mice exhibited a high tumor selectivity of Polycisplatin by EPR effect despite the relatively small particle size. In order to compare the in vivo efficacy of Polycisplatin and cisplatin, their xenograft trials were performed using nude mice against the human gastric cell line MKN-28. Polycisplatin exhibited slightly less tumor suppression effect compared with cisplatin at the same dose of 1.95 mg Pt/kg, which is the maximum tolerate dose of cisplatin, but at the higher double dose of 3.9 mg Pt/kg, Polycisplatin exhibited a little better efficacy than cisplatin. Furthermore, mice treated with cisplatin at the dose of 1.95 mg Pt/kg exhibited severe body weight decrease by about 25%, while mice treated with Polycisplatin did not show serious body weight decrease even at its double dose of 3.9 mg Pt/kg. Furthermore, kidney indicators including kidney index, BUN, and creatinine values measured displayed that Polycisplatin is much less nephrotoxic than cisplatin. Conclusion Nanoparticular Polycisplatin was successfully prepared by conjugating cisplatin to a hydrophilic polyphosphazene carrier polymer using the acid-cleavable cis-aconitic acid. Polycisplatin nanoparticles exhibit excellent tumor-targeting properties by EPR effect. The xenograft trials exhibited excellent antitumor efficacy and reduced systemic toxicity of Polycisplatin.
-
Design of Theranostic Nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene–docetaxel conjugate
International journal of nanomedicine, 2017Co-Authors: Yong Joo Jun, Prakash G Avaji, Jung Hyun Park, Kyung Su Park, Kyung Eun Lee, Hwa Jeong Lee, Youn Soo SohnAbstract:To prepare an efficient Theranostic polyphosphazene-docetaxel (DTX) conjugate, a new drug delivery system was designed by grafting a multifunctional lysine ethylester (LysOEt) as a spacer group along with methoxy poly(ethylene glycol) (MPEG) to the polyphosphazene backbone ([NP]n), and then DTX was conjugated to the carrier polymer using acid-cleavable cis-aconitic acid (AA) as a linker. The resultant polyphosphazene-DTX conjugate, formulated as [NP(MPEG550)3(Lys-OEt)(AA)(DTX)]n and named "Polytaxel", exhibited high water solubility and stability by forming stable polymeric micelles as shown in its transmission electron microscopy image and dynamic light scattering measurements. Another important aspect of Polytaxel is that it can easily be labeled with various imaging agents using the lysine amino group, enabling studies on various aspects, such as its organ distribution, tumor-targeting properties, pharmacokinetics, toxicity, and excretion. The pharmacokinetics of Polytaxel was remarkably improved, with prolonged elimination half-life and enhanced area under the curve. Ex vivo imaging study of cyanine dye-labeled Polytaxel showed that intravenously injected Polytaxel is long circulating in the blood stream and selectively accumulates in tumor tissues. Polytaxel distributed in other organs was cleared from all major organs at ~6 weeks after injection. The in vitro study of DTX release from the carrier polymer showed that >95% of conjugated DTX was released at pH 5.4 over a period of 7 days. Xenograft trials of Polytaxel using nude mice against the human gastric tumor cell line MKN-28 showed complete tumor regression, with low systemic toxicity. Polytaxel is currently in preclinical study.
-
design of Theranostic Nanomedicine ii synthesis and physicochemical properties of a biocompatible polyphosphazene docetaxel conjugate
International Journal of Nanomedicine, 2017Co-Authors: Yong Joo Jun, Prakash G Avaji, Jung Hyun Park, Kyung Su Park, Kyung Eun Lee, Hwa Jeong Lee, Youn Soo SohnAbstract:To prepare an efficient Theranostic polyphosphazene-docetaxel (DTX) conjugate, a new drug delivery system was designed by grafting a multifunctional lysine ethylester (LysOEt) as a spacer group along with methoxy poly(ethylene glycol) (MPEG) to the polyphosphazene backbone ([NP]n), and then DTX was conjugated to the carrier polymer using acid-cleavable cis-aconitic acid (AA) as a linker. The resultant polyphosphazene-DTX conjugate, formulated as [NP(MPEG550)3(Lys-OEt)(AA)(DTX)]n and named "Polytaxel", exhibited high water solubility and stability by forming stable polymeric micelles as shown in its transmission electron microscopy image and dynamic light scattering measurements. Another important aspect of Polytaxel is that it can easily be labeled with various imaging agents using the lysine amino group, enabling studies on various aspects, such as its organ distribution, tumor-targeting properties, pharmacokinetics, toxicity, and excretion. The pharmacokinetics of Polytaxel was remarkably improved, with prolonged elimination half-life and enhanced area under the curve. Ex vivo imaging study of cyanine dye-labeled Polytaxel showed that intravenously injected Polytaxel is long circulating in the blood stream and selectively accumulates in tumor tissues. Polytaxel distributed in other organs was cleared from all major organs at ~6 weeks after injection. The in vitro study of DTX release from the carrier polymer showed that >95% of conjugated DTX was released at pH 5.4 over a period of 7 days. Xenograft trials of Polytaxel using nude mice against the human gastric tumor cell line MKN-28 showed complete tumor regression, with low systemic toxicity. Polytaxel is currently in preclinical study.
-
Design of a novel Theranostic Nanomedicine: synthesis and physicochemical properties of a biocompatible polyphosphazene-platinum(II) conjugate.
International journal of nanomedicine, 2016Co-Authors: Prakash G Avaji, Jung Hyun Park, Hyun Jeong Lee, Yong Joo Jun, Kyung Su Park, Kyung Eun Lee, Soo-jin Choi, Hwa Jeong Lee, Youn Soo SohnAbstract:To develop a Theranostic Nanomedicine involving the antitumor-active moiety (dach)Pt(II) (dach: trans-(±)-1,2-diaminocyclohexane) of oxaliplatin (OX), a new biocompatible polyphosphazene carrier polymer was designed by grafting with a methoxy poly(ethylene glycol) (MPEG) to increase duration of circulation in the blood and with aminoethanol (AE) as a spacer group. The antitumor (dach)Pt moiety was conjugated to the carrier polymer using cis-aconitic acid (AA) as a linker, resulting in a polymer conjugate formulated as [NP(MPEG550)(AE-AA)Pt(dach)]n, named "Polyplatin" (PP). PP was found to self-assemble into very stable polymeric nanoparticles with a mean diameter of 55.1 nm and a critical aggregation concentration of 18.5 mg/L in saline. PP could easily be labeled with a fluorescence dye such as Cy5.5 for imaging studies. The time-dependent ex vivo image studies on organ distributions and clearance of Cy-labeled PP have shown that PP accumulated in the tumor with high selectivity by the enhanced permeability and retention effect but was cleared out from all the major organs including the liver in about 4 weeks postinjection. Another time-dependent bioimaging study on distribution and clearance of PP in mouse kidney using laser ablation inductively coupled plasma mass spectroscopy has shown that PP accumulates much less in kidney and is more rapidly excreted than monomeric OX, which is in accord with the very low acute toxicity of PP as shown by its high LD50 value of more than 2000 mg/kg. The pharmacokinetic study of PP has shown that it has a much longer half-life (t 1/2β) of 13.3 hours compared with the 5.21 hours of OX and about a 20 times higher area under the curve value of 42,850.8 ng h/mL compared with the 2,320.4 ng h/mL of OX. The nude mouse xenograft trials of PP against the gastric MKN-28 tumor cell line exhibited remarkably better tumor efficacy compared with OX at the higher tolerated dose, with lower systemic toxicity.
Yubin Huang - One of the best experts on this subject based on the ideXlab platform.
-
tailoring platinum iv amphiphiles for self targeting all in one assemblies as precise multimodal Theranostic Nanomedicine
ACS Nano, 2018Co-Authors: Qingfei Zhang, Xing-jie Liang, Xiaoyuan Chen, Haihua Xiao, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Drug, targeting ligand, and imaging agent are the three essential components in a nanoparticle-based drug delivery system. However, tremendous batch-to-batch variation of composition and drug content typically accompany the current approaches of building these components together. Herein, we report the design of photoactivatable platinum(IV) (Pt(IV)) amphiphiles containing one or two hydrophilic lactose targeting ligands per hydrophobic Pt(IV) prodrug for an all-in-one precise Nanomedicine. Self-assembly of these Pt(IV) amphiphiles results in either micelle or vesicle formation with a fixed Pt/targeting moiety ratio and a constantly high content of Pt. The micelles and vesicles are capable of hepatoma cell-targeting, fluorescence/Pt-based CT imaging and have shown effective anticancer efficacy under laser irradiation in vitro and in vivo. This photoactivatable, active self-targeting, and multimodal Theranostic amphiphile strategy shows great potential in constructing precise Nanomedicine.
-
dual drug backboned shattering polymeric Theranostic Nanomedicine for synergistic eradication of patient derived lung cancer
Advanced Materials, 2018Co-Authors: Yuwei Cong, Xing-jie Liang, Haihua Xiao, Hejian Xiong, Zigui Wang, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Most of the current nanoparticle-based therapeutics worldwide failing in clinical trials face three major challenges: (i) lack of an optimum drug delivery platform with precise composition, (ii) lack of a method of directly monitoring the fate of a specific drug rather than using any other labelling molecules as a compromise, and (iii) lack of reliable cancer models with high fidelity for drug screen and evaluation. Here, starting from a PP2A inhibitor demethylcantharidin (DMC) and cisplatin, the design of a dual sensitive dual drug backboned shattering polymer (DDBSP) with exact composition at a fixed DMC/Pt ratio for precise Nanomedicine is shown. DDBSP self-assembled nanoparticle (DD-NP) can be triggered intracellularly to break down in a chain-shattering manner to release the dual drugs payload. Moreover, DD-NP with extremely high Pt heavy metal content in the polymer chain can directly track the drug itself via Pt-based drug-mediated computer tomography and ICP-MS both in vitro and in vivo. Finally, DD-NP is used to eradicate the tumor burden on a high-fidelity patient-derived lung cancer model for the first time.
-
Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine
2018Co-Authors: Qingfei Zhang, Xing-jie Liang, Xiaoyuan Chen, Haihua Xiao, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Drug, targeting ligand, and imaging agent are the three essential components in a nanoparticle-based drug delivery system. However, tremendous batch-to-batch variation of composition and drug content typically accompany the current approaches of building these components together. Herein, we report the design of photoactivatable platinum(IV) (Pt(IV)) amphiphiles containing one or two hydrophilic lactose targeting ligands per hydrophobic Pt(IV) prodrug for an all-in-one precise Nanomedicine. Self-assembly of these Pt(IV) amphiphiles results in either micelle or vesicle formation with a fixed Pt/targeting moiety ratio and a constantly high content of Pt. The micelles and vesicles are capable of hepatoma cell-targeting, fluorescence/Pt-based CT imaging and have shown effective anticancer efficacy under laser irradiation in vitro and in vivo. This photoactivatable, active self-targeting, and multimodal Theranostic amphiphile strategy shows great potential in constructing precise Nanomedicine
Xing-jie Liang - One of the best experts on this subject based on the ideXlab platform.
-
tailoring platinum iv amphiphiles for self targeting all in one assemblies as precise multimodal Theranostic Nanomedicine
ACS Nano, 2018Co-Authors: Qingfei Zhang, Xing-jie Liang, Xiaoyuan Chen, Haihua Xiao, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Drug, targeting ligand, and imaging agent are the three essential components in a nanoparticle-based drug delivery system. However, tremendous batch-to-batch variation of composition and drug content typically accompany the current approaches of building these components together. Herein, we report the design of photoactivatable platinum(IV) (Pt(IV)) amphiphiles containing one or two hydrophilic lactose targeting ligands per hydrophobic Pt(IV) prodrug for an all-in-one precise Nanomedicine. Self-assembly of these Pt(IV) amphiphiles results in either micelle or vesicle formation with a fixed Pt/targeting moiety ratio and a constantly high content of Pt. The micelles and vesicles are capable of hepatoma cell-targeting, fluorescence/Pt-based CT imaging and have shown effective anticancer efficacy under laser irradiation in vitro and in vivo. This photoactivatable, active self-targeting, and multimodal Theranostic amphiphile strategy shows great potential in constructing precise Nanomedicine.
-
abstract 635 osteopontin targeted Theranostic Nanomedicine for dual modality imaging guided photodynamic therapy for vulnerable atherosclerotic plaque
Arteriosclerosis Thrombosis and Vascular Biology, 2018Co-Authors: Weisheng Guo, Xing-jie Liang, Yabin Wang, Feng CaoAbstract:Background: Macrophage infiltration plays a vital role in vulnerable atherosclerotic plaque (VASP) progression. Our previous work has demonstrated that osteopontin (OPN), overexpressed in foamy mac...
-
dual drug backboned shattering polymeric Theranostic Nanomedicine for synergistic eradication of patient derived lung cancer
Advanced Materials, 2018Co-Authors: Yuwei Cong, Xing-jie Liang, Haihua Xiao, Hejian Xiong, Zigui Wang, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Most of the current nanoparticle-based therapeutics worldwide failing in clinical trials face three major challenges: (i) lack of an optimum drug delivery platform with precise composition, (ii) lack of a method of directly monitoring the fate of a specific drug rather than using any other labelling molecules as a compromise, and (iii) lack of reliable cancer models with high fidelity for drug screen and evaluation. Here, starting from a PP2A inhibitor demethylcantharidin (DMC) and cisplatin, the design of a dual sensitive dual drug backboned shattering polymer (DDBSP) with exact composition at a fixed DMC/Pt ratio for precise Nanomedicine is shown. DDBSP self-assembled nanoparticle (DD-NP) can be triggered intracellularly to break down in a chain-shattering manner to release the dual drugs payload. Moreover, DD-NP with extremely high Pt heavy metal content in the polymer chain can directly track the drug itself via Pt-based drug-mediated computer tomography and ICP-MS both in vitro and in vivo. Finally, DD-NP is used to eradicate the tumor burden on a high-fidelity patient-derived lung cancer model for the first time.
-
Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine
2018Co-Authors: Qingfei Zhang, Xing-jie Liang, Xiaoyuan Chen, Haihua Xiao, Jianxun Ding, Xuesi Chen, Dongfang Zhou, Yubin HuangAbstract:Drug, targeting ligand, and imaging agent are the three essential components in a nanoparticle-based drug delivery system. However, tremendous batch-to-batch variation of composition and drug content typically accompany the current approaches of building these components together. Herein, we report the design of photoactivatable platinum(IV) (Pt(IV)) amphiphiles containing one or two hydrophilic lactose targeting ligands per hydrophobic Pt(IV) prodrug for an all-in-one precise Nanomedicine. Self-assembly of these Pt(IV) amphiphiles results in either micelle or vesicle formation with a fixed Pt/targeting moiety ratio and a constantly high content of Pt. The micelles and vesicles are capable of hepatoma cell-targeting, fluorescence/Pt-based CT imaging and have shown effective anticancer efficacy under laser irradiation in vitro and in vivo. This photoactivatable, active self-targeting, and multimodal Theranostic amphiphile strategy shows great potential in constructing precise Nanomedicine
-
Biomedical nanomaterials for imaging-guided cancer therapy
Nanoscale, 2012Co-Authors: Yuran Huang, Weipeng Cao, Kaiyong Cai, Sha He, Xing-jie LiangAbstract:To date, even though various kinds of nanomaterials have been evaluated over the years in order to develop effective cancer therapy, there is still significant challenges in the improvement of the capabilities of nano-carriers. Developing a new Theranostic Nanomedicine platform for imaging-guided, visualized cancer therapy is currently a promising way to enhance therapeutic efficiency and reduce side effects. Firstly, conventional imaging technologies are reviewed with their advantages and disadvantages, respectively. Then, advanced biomedical materials for multimodal imaging are illustrated in detail, including representative examples for various dual-modalities and triple-modalities. Besides conventional cancer treatment (chemotherapy, radiotherapy), current biomaterials are also summarized for novel cancer therapy based on hyperthermia, photothermal, photodynamic effects, and clinical imaging-guided surgery. In conclusion, biomedical materials for imaging-guided therapy are becoming one of the mainstream treatments for cancer in the future. It is hoped that this review might provide new impetus to understand nanotechnology and nanomaterials employed for imaging-guided cancer therapy.
Jinming Gao - One of the best experts on this subject based on the ideXlab platform.
-
superparamagnetic iron oxide nanoparticles amplifying ros stress to improve anticancer drug efficacy
Theranostics, 2013Co-Authors: Gang Huang, Huabing Chen, Ying Dong, Xiuquan Luo, Zachary R Moore, Erik A Bey, David A Boothman, Jinming GaoAbstract:Superparamagnetic iron oxide nanoparticles (SPION) are an important and versatile nano- platform with broad biological applications. Despite extensive studies, the biological and pharmacological activities of SPION have not been exploited in therapeutic applications. Recently, β-lapachone (β-lap), a novel anticancer drug, has shown considerable cancer specificity by selectively increasing reactive oxygen species (ROS) stress in cancer cells. In this study, we report that pH-responsive SPION-micelles can synergize with β-lap for improved cancer therapy. These SPION-micelles selectively release iron ions inside cancer cells, which interact with hydrogen peroxide (H2O2) generated from β-lap in a tumor-specific, NQO1-dependent manner. Through Fenton reactions, these iron ions escalate the ROS stress in β-lap-exposed cancer cells, thereby greatly enhancing the therapeutic index of β-lap. More specifically, a 10-fold increase in ROS stress was detected in β-lap-exposed cells pretreated with SPION-micelles over those treated with β-lap alone, which also correlates with significantly increased cell death. Catalase treatment of cells or administration of an iron chelator can block the therapeutic synergy. Our data suggest that incorporation of SPION-micelles with ROS-generating drugs can potentially improve drug efficacy during cancer treatment, thereby provides a synergistic strategy to integrate imaging and therapeutic functions in the development of Theranostic Nanomedicine.
-
Multifunctional Micellar Nanomedicine for Cancer Therapy
Experimental biology and medicine (Maywood N.J.), 2008Co-Authors: Elvin Blanco, Baran D. Sumer, Chase W. Kessinger, Jinming GaoAbstract:Polymeric micelles are supramolecular, core-shell nanoparticles that offer considerable advantages for cancer diagnosis and therapy. Their relatively small size (10-100 nm), ability to solubilize hydrophobic drugs as well as imaging agents, and improved pharmacokinetics provide a useful bioengineering platform for cancer applications. Several polymeric micelle formulations are currently undergoing phase I/II clinical trials, which have shown improved antitumor efficacy and reduced systemic toxicity. This minireview will focus on recent advancements in the multifunctional design of micellar Nanomedicine with tumor targeting, stimulated drug release, and cancer imaging capabilities. Such functionalization strategies result in enhanced micellar accumulation at tumor sites, higher drug bioavailability, as well as improved tumor diagnosis and visualization of therapy. Ultimately, integrated nanotherapeutic systems (e.g., Theranostic Nanomedicine) may prove essential to address the challenges of tumor heterogeneity and adaptive resistance to achieve efficacious treatment of cancer.
-
Theranostic Nanomedicine for cancer
Nanomedicine (London England), 2008Co-Authors: Baran D. Sumer, Jinming GaoAbstract:Baran Sumer1, Jinming Gao2† †Author for correspondence 1Department of Otolaryngology, Head and Neck Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA Tel.: +1 214 648 3102; Fax: +1 214 648 2246; E-mail: baran.sumer@ utsouthwestern.edu 2Department of Pharmacology, Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75093, USA Tel.: +1 214 645 6370; Fax: +1 214 645 6347; E-mail: jinming.gao@ utsouthwestern.edu ‘Over recent decades, there has been explosive development of a variety of nanotechnology platforms to diagnose and treat cancer.’